Difference in protective effects of GIP and GLP‑1 on endothelial cells according to cyclic adenosine monophosphate response

Lim,Dong‑Mee; Park,Keun‑Young; Hwang,Won‑Min; Kim,Ju‑Young; Kim,Byung‑Joon

doi:10.3892/etm.2017.4279

Difference in protective effects of GIP and GLP‑1 on endothelial cells according to cyclic adenosine monophosphate response

Authors:
- Dong‑Mee Lim
- Keun‑Young Park
- Won‑Min Hwang
- Ju‑Young Kim
- Byung‑Joon Kim
View Affiliations

Affiliations: Division of Endocrinology, Department of Internal Medicine, Konyang University School of Medicine, Daejeon 35365, Republic of Korea, Division of Nephrology, Department of Internal Medicine, Konyang University School of Medicine, Daejeon 35365, Republic of Korea, Imaging Science‑Based Lung and Bone Diseases Research Center, Wonkwang University, Iksan, Jeonbuk 54538, Republic of Korea, Division of Endocrinology, Department of Internal Medicine, Gachon University School of Medicine, Incheon 21565, Republic of Korea
Published online on: March 29, 2017 https://doi.org/10.3892/etm.2017.4279
Pages: 2558-2564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide 1 (GLP‑1) are present in vascular endothelial cells. Previous studies investigating euglycemic status have demonstrated that GIP is directly involved in the physiology of blood vessels by controlling the blood flow rate of portal veins and that GLP‑1 has a protective effect on blood vessels by acting on endothelial cells. However, to the best of our knowledge, the effects of GIP and GLP‑1 on endothelial cells in patients with hyperglycemia remain unknown. Therefore, the present study investigated whether the effect of the incretin hormones GLP‑1 and GIP differed with regards to the reversal of endothelial cell dysfunction caused by hyperglycemia. The production of nitric oxide (NO) was measured using the Griess reagent system kit and the expression of cyclic adenosine monophosphate (cAMP) in the cell was measured at a wavelength of 405 nm with the ELISA reader using the cyclic AMP EIA kit. Exposure of human umbilical vein endothelial cells (HUVEC) to a high glucose concentration decreased NO and endothelial nitric oxide synthase (eNOS) levels but increased inducible NOS (iNOS) levels. However, when HUVECs were pretreated with GLP‑1, a reduction of iNOS expression was observed and the expression of eNOS and NO were increased, as opposed to pretreatment with GIP. The results differed according to the response of cAMP, the second messenger of incretin hormones: The GIP pretreatment group did not exhibit an increase in cAMP levels while the GLP‑1 pretreatment group did. The results of the present study provide evidence that GLP‑1, but not GIP, has a protective effect on endothelial function associated with cardiovascular disease, as it is associated with increased eNOS expression and the levels of NO. This effect may be due to an increase in the cAMP concentration during hyperglycemic events.

View Figures

View References

1	Rask-Madsen C and King GL: Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 3:46–56. 2007. View Article : Google Scholar : PubMed/NCBI
2	ACCORD Study Group, ; Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr..Probstfield JL, Cushman WC, Ginsberg HN, et al: Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 364:818–828. 2011. View Article : Google Scholar : PubMed/NCBI
3	Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I and Kleinert H: Nitric oxide synthase isozymes: Characterization, purification, molecular cloning and functions. Hypertension. 23:1121–1131. 1994. View Article : Google Scholar : PubMed/NCBI
4	Wright E Jr..Scism-Bacon JL and Glass LC: Oxidative stress in type 2 diabetes: The role of fasting and postprandial glycaemia. Int J Clin Pract. 60:308–314. 2006. View Article : Google Scholar : PubMed/NCBI
5	Schäfer A and Bauersachs J: Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 6:52–60. 2008. View Article : Google Scholar : PubMed/NCBI
6	Davignon J and Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation. 109(23 Suppl 1): III27–III32. 2004.PubMed/NCBI
7	Vilsbøll T, Krarup T, Madsbad S and Holst JJ: Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 114:115–121. 2003. View Article : Google Scholar : PubMed/NCBI
8	Kim W and Egan JM: The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 60:470–512. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kogire M, Inoue K, Sumi S, Doi R, Yun M, Kaji H and Tobe T: Effects of gastric inhibitory polypeptide and glucagon on portal venous and hepatic arterial flow in conscious dogs. Dig Dis Sci. 37:1666–1670. 1992. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Ojima A, Matsui T, Maeda S, Takeuchi M and Yamagishi S: Glucose-dependent insulinotropic polypeptide (GIp) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties. Horm Metab Res. 44:501–505. 2012. View Article : Google Scholar : PubMed/NCBI
12	Forst T, Weber MM and Pfützner A: Cardiovascular benefits of GLP-1-based therapies in patients with diabetes mellitus type 2: Effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res. 2012:6354722012. View Article : Google Scholar : PubMed/NCBI
13	Holst JJ: The physiology of glucagon-like peptide 1. Physiol Rev. 87:1409–1439. 2007. View Article : Google Scholar : PubMed/NCBI
14	Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y and Drucker DJ: Extrapancreatic incretin receptors modulate glucose homeostasis, body weight and energy expenditure. J Clin Invest. 117:143–152. 2007. View Article : Google Scholar : PubMed/NCBI
15	Hong JY, Park KY, Kim BJ, Hwang WM, Kim DH and Lim DM: Effects of short-term exenatide treatment on regional fat distribution, glycated hemoglobin levels and aortic pulse wave velocity of obese type 2 diabetes mellitus patients. Endocrinol Metab (Seoul). 31:80–85. 2016. View Article : Google Scholar : PubMed/NCBI
16	Nichols WW: Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens. 18:3S–10S. 2005. View Article : Google Scholar : PubMed/NCBI
17	Anderson TJ: Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. Can J Cardiol. 22 Suppl B:72B–80B. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ding L and Zhang J: Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin. 33:75–81. 2012. View Article : Google Scholar : PubMed/NCBI
19	MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE and Wheeler MB: The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 51 Suppl 3:S434–S442. 2002. View Article : Google Scholar : PubMed/NCBI
20	Zhong Q, Bollag RJ, Dransfield DT, Gasalla-Herraiz J, Ding KH, Min L and Isales CM: Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides. 21:1427–1432. 2000. View Article : Google Scholar : PubMed/NCBI
21	D'Angelo G, Lee H and Weiner RI: CAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking raf activation. J Cell Biochem. 67:353–366. 1997. View Article : Google Scholar : PubMed/NCBI
22	Ding KH, Zhong Q and Isales CM: Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: Role of endothelin-1. Am J Physiol Endocrinol Metab. 285:E390–E396. 2003. View Article : Google Scholar : PubMed/NCBI
23	Eriksson L, Saxelin R, Röhl S, Roy J, Caidahl K, Nyström T, Hedin U and Razuvaev A: Glucagon like peptide-1 receptor activation does not affect re-endothelization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of arterial injury. J Vasc Res. 52:41–52. 2015. View Article : Google Scholar : PubMed/NCBI
24	Ge GH, Dou HJ, Yang SS, Ma JW, Cheng WB, Qiao ZY, Hou YM and Fang WY: Glucagon-like peptide-1 protects against cardiac microvascular endothelial cells injured by high glucose. Asian Pac J Trop Med. 8:73–78. 2015. View Article : Google Scholar : PubMed/NCBI
25	Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, et al: Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes. 62:1697–1708. 2013. View Article : Google Scholar : PubMed/NCBI
26	Lüscher TF and Barton M: Biology of the endothelium. Clin Cardiol. 20(11 Suppl 2): II3–II10. 1997.
27	Forbes JM and Cooper ME: Mechanisms of diabetic complications. Physiol Rev. 93:137–188. 2013. View Article : Google Scholar : PubMed/NCBI
28	Deanfield JE, Halcox JP and Rabelink TJ: Endothelial function and dysfunction: Testing and clinical relevance. Circulation. 115:1285–1295. 2007.PubMed/NCBI
29	Belz GG and Mohr-Kahaly S: Cacoa and dark chocolate in cardiovascular prevention? Dtsch Med Wochenschr. 136:2657–2663. 2011.(In German). PubMed/NCBI